ICMJE DISCLOSURE FORM

Date: 2/1/2026

Your Name: Lijckle van der Laan

Manuscript Title: Conservatieve behandeling van oudere patiënten met chronische ledemaat bedreigende ischemie (CLBI) is passende zorg binnen de huidige tijdgeest

Manuscript Number (if known): D8966

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☒ None	
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☐ **None**	
		MedZO, ZonMw grant	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☐ **None**	
		Artivion payments to me	
		Medtronic payments to me	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ **None**	
		Voorzitter satellietsymposium Artivion's Branched Solutions for Aorto-Iliac Disease. Vaatdagen,2025	
		De FAVOR-polikliniek; samenwerking klinisch geriater en vaatchirurg voor de oudere patiënt met ernstig perifeer vaatlijden. CarVascG congres, Ede.2024	
		Exploring Medtronic's app designed for the patient journey. Workshop, European Vascular Course, Maastricht.2023	
6	Payment for expert testimony	☒ **None**	
7	Support for attending meetings and/or travel	☐ **None**	
8	Patents planned, issued or pending	☐ **None**	
		EVC 2023	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ **None**	
		Content Reviewer of the European Society for Vascular Surgery (ESVS), Clinical Practice Guidelines on Amputations.unpaid	
		Board member Dutch Vascular Society (NVvV); secretary of quality.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Chairman CAB (Clinical Audit Board) Dutch Audit for Carotid Interventions (DACI) and Dutch Surgical Aneurysm Audit (DSAA).	
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☒ **None**	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.